BioMarin Pharmaceutical | BMRN - 贸易债权人



金融业
股票价格
USD
资产
USD 11.72B
现金及等价物
USD 874.01M
销售成本
USD 276.29M
流动资产
USD 3.97B
流动负债
USD 1.66B
债务
USD 1.44B
EBIT
USD 105.61M
EBITDA
USD 146.05M
员工
3.04K
EPS每股收益
USD 1.2
股本和储备
USD 6.32B
销售毛利
USD 713.42M
债务利息支出
USD 63.3M
利息收入
USD 22.56M
贷款资金
USD 3.53B
市值
USD 12.29B
净收入
USD 44.76M
营业费用
USD 6.32B
营业利润
USD 105.61M
普通股股本
USD 193.54M
PE价格收益
21.07
税前利润
USD 141.2M
销售收入
USD 990M
销售和管理费用
USD 395.55M
股票
USD 1.78B
贸易债权人
USD 913.67M
应收帐款人
USD 1.06B


贸易债权人 更改 日
Acadia Pharmaceuticals USD 44.57M 32.32M 2026-06
Agios Pharmaceuticals USD 16.34M 2.6M 2026-06
Alnylam Pharmaceuticals USD 108.02M 18.61M 2026-06
Amgen USD 2.86B 16.65B 2026-06
Bayer EUR 6.39B 192M 2026-06
Biogen USD 403.9M 45.4M 2026-06
BioMarin Pharmaceutical USD 913.67M 120.52M 2026-06
Gilead Sciences USD 645M 70M 2026-03
Incyte USD 1.39B 1.16B 2026-06
Insmed USD 74.55M 1.18M 2026-06
Ionis Pharmaceuticals USD 47.7M 21.67M 2026-06
Moderna USD 167M 6M 2026-06
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
PTC Therapeutics USD 40.45M 14.96M 2026-06
Puma Biotechnology USD 6.39M 962K 2025-09
Regeneron Pharmaceuticals USD 1.16B 132.2M 2026-06
Roche Holding CHF 5.54B 237M 2026-06
Sangamo BioSciences USD 10.74M 7.46M 2025-06
Sanofi EUR 22.71B 219M 2026-03
Sarepta Therapeutics USD 50.98M 19.39M 2026-06
Ultragenyx Pharmaceutical USD 39M 3M 2026-06
United Therapeutics USD 497.8M 500K 2026-06
Vertex Pharmaceuticals USD 3.61B 135M 2026-06